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Summary
Although transfusions and chelation therapy have improved
survival of patients afflicted with Thalassemia Major (TM), en-
docrine alterations are still common complications. Particular-
ly, hypogonadism plays an important role in the aetiology of
osteoporosis in these patients. It is clear that in most patients
the gonadal failure is a consequence of a pituitary damage
and that a hypogonadotropic hypogonadism occurs; never-
theless, also a gonadal damage because of iron deposition
may be a further cause of hypogonadism. Prevalence of the
pubertal failure ranges between 50 to 80% of the cases. In
some studies ferritin levels have been correlated with hypogo-
nadism, suggesting that improvement of chelation treatments
may prevent or reduce the appearance of hypogonadism in
TM patients. Treatment with HRT has shown conflicting re-
sults, but patients who started the treatment in young age pre-
sent better results than those who started later. However we
may conclude that HRT is an important treatment option but
should be prescribed in early age and associated with biphos-
phonates.
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Beta thalassemia major (TM) is an important health concern in
many countries, mostly in the Mediterranean area, in the Mid-
dle East, India, East Asia. In 1988 a report from the WHO doc-
umented that almost 50000 children per year were born with
TM. 
In the last decades, improved programs of transfusional and
chelation therapy have permitted to TM patients to survive until
their forties or fifties and to get a better quality of life (1). How-
ever, several complications progressively arise and in particu-
lar endocrine alterations are common with diabetes, hypothy-
roidism, hypoparathyroidism, and hypogonadism being well
known complications of adult thalassemia major (2-4).
More recently, in adult TM patients, bone mass deficiency has
been recognised as a major problem that may cause patholog-
ic fractures and limb deformities and greatly worsen the quality
of life of these patients (5, 6). The etiology of bone mass defi-
ciency in thalassemia is still unclear and many factors have
been suggested as possible causes, including IGF-I deficiency,
low vitamin D levels, alterations of genes related to collagen
synthesis, bone cortical thinning because of bone marrow ex-
pansion and altered levels of some oligoelements such as zinc
and copper (7). However, a main role is probably played by hy-
pogonadism that is a hallmark of adult TM patients. 
In this brief review, we will examine the characteristics of hy-
pogonadism in TM patients and the possible link between hy-
pogonadism and bone mass deficiency. Finally, we will discuss
the role of the hormonal substitutive therapy in the prevention
and treatment of bone mass deficiency in TM. 
Prevalence and characteristics of gonadal failure 
in thalassemia major
Most TM patients present a delayed or absent puberty. In the
patients who present puberty (at normal or late age), a gonadal
failure often progressively occurs with appearance of menstrual
disorders and anovulation in women and spermatic abnormali-
ties and reduced sexual activity in males. While it was initially
suggested that a primary gonadal deficiency (a hyperg-
onadotropic hypogonadism) occurs in TM patients, it is now
clear that in most patients the gonadal failure is a consequence
of a pituitary damage and that a hypogonadotropic hypogo-
nadism occurs. Primitive gonadal damage may also occur but
appears generally later (sometimes also in patients with hypog-
onadotropic hypogonadism). Therefore, in some adult TM pa-
tients (generally after the third decade) a mixed hypogonadism
(central and gonadal) may be present (8). 
All studies have documented that the prevalence of hypogo-
nadism in adult TM patients is very high. In an Italian multicen-
tric study, failure of the puberty was observed in 51% of the
male and in 47% of female subjects. Between the female pa-
tients who reached a normal menarche, 23% presented a sec-
ondary amenorrhea and 11.6% oligomenorrhea (9). 
In an Iranian study, puberty was delayed or absent in 72.6% of
females and 80.8 % of the males and a disturbance of gonadal
function was the most common endocrinopathy. 
Several years ago, we have shown that about 70% of adult TM
patients (both males and females) present some degree of hy-
pogonadism (19). More recently, studying 30 adult TM women
(mean age 28.5 ± 1.3 years), we found that TM patients had
lower serum levels of LH, FSH and estradiol (Figure 1) than
controls of similar age (10). A 80% prevalence of hypogo-
nadotropic hypogonadism was found and 20% of patients with
hypogonadotropic hypogonadism presented also some evi-
dence of primary gonadal failure. 
A subset of adult TM patients present normal gonadal function.
In our study, six adult TM women had normal ovulatory cycles
with normal circulating levels of LH, FSH, estradiol and proges-
terone. Two of these TM patients previously had spontaneous
successful pregnancies. Therefore, while most TM patients
progressively develop a sexual hormone deficiency, some re-
main eugonadal. It is unclear what mechanism may determine
these differences. In fact, while it is possible that differences in
chelation or transfusional programs may explain it, we did not
find any evidence of it and serum ferritin levels were not signifi-
cantly different in eugonadal compared to hypogonadic adult
TM women.
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Causes of hypogonadism in adult TM patients 
It has been suggested that in TM patients the hypothalamus
and the pituitary are damaged by the iron overload (11). In
fact the pituitary gland is very sensitive to iron and also a
modest deposition may impair its functionality. Histological
studies have confirmed the damage of the pituitary gland by
iron overload in TM patients (12) and MRI has shown a signif-
icantly smaller anterior pituitary volume (13). Other studies
have shown that iron overload may also directly damage the
gonads (14). Therefore, it may be assumed that the hypogo-
nadism of adult TM patients is mainly a consequence of the
iron deposit. 
Some authors have reported higher ferritin levels in subjects
who had hypogonadism compared to those with normal go-
nadal function (15). Ferritin is the protein that stores iron intra-
cellularly and when its capability is exceeded an excess of ac-
tive iron is released and catalyses the formation of free radi-
cals. Free radicals may damage membrane lipids, leading to
mitochondrial and lysosomal damage and finally to cell death.
Because of these findings it has been suggested that improve-
ment of chelation treatments may prevent or reduce the ap-
pearance of hypogonadism in TM patients (16). While it may
be probable, other studies did not find such correlations and
our normogonadic patients had the same transfusion and
chelation treatment than hypogonadic patients. Moreover,
while hypogonadic patients had slightly higher ferritin circulat-
ing levels, the difference with normogonadic patients was not
significant.
Relationships between hypogonadism and bone mass 
deficiency in TM
It is well known that sexual hormone deficiency determines
an alteration of bone metabolism with increased bone resorp-
tion and progressive evolution towards osteoporosis. While
most studies have been conducted in menopausal women, it
is clear, from clinical and experimental data, that sexual hor-
mone deficiency may determine osteopenia or osteoporosis
at any age and in both sexes. Because of it and although
many other possible causes are present in thalassemia, hy-
pogonadism may have a main role in determining bone mass
d e f i c i e n c y .
Consistent with this hypothesis, we have shown that in adult
TM patients a direct correlation between low bone mass and
reduced estradiol exists, suggesting that reduced bone mass in
many TM patients is mostly dependent on sex hormone defi-
ciency (10). Moreover, hypogonadic TM patients had lower L1-
L4 z score (Figure 2) and higher levels of bone markers (Figure
3) than eugonadal TM patients. All these data confirm that go-
nadal failure plays a main role in inducing bone mass deficien-
cy of adult TM patients. 
HRT effects on bone mass deficiency
Because this important role of hypogonadism, we should ex-
pect that hormonal replacement therapy (HRT) corrects or pre-
vents bone mass deficiency in adult TM patients. Conflicting re-
sults have been presented with some studies indicating a clear
improvement and other giving doubtful results. In our recent
study, we found that female TM patients treated with HRT still
have reduced bone mass and increased bone turnover com-
pared to normal women of similar age. However, patients who
started the HRT in younger age had better results than patients
who started the treatment later. Maybe, it is important to start
the treatment early, at the pubertal age. On the other hand, it
cannot be excluded that HRT is not sufficient because other
factors contribute to the bone mass deficiency of TM patients.
Consistent with our results, Lasco et al. found that bone mass,
measured by DEXA, was lower in all TM patients than in con-
trols, but the difference was more marked in patients who didn’t
receive HRT (17). We can conclude that HRT is an important
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part of the treatment of bone mass deficiency in adult TM pa-
tients but that the treatment has to be started early and that of-
ten alone is not sufficient to normalize bone mass.
Because of the disappointing results of HRT on bone mass in
adult TM patients, it has been suggested to associate HRT and
bisphosphonates (18). Limited experience is available but the
results of our group and of other authors suggest that the re-
sults may be better than with HRT alone.
Conclusions
Hypogonadism is very common in adult TM patients and may
be present in about 80% of the patients. It is important to as-
sess hypothalamic-pituitary-gonadal function in young women
with beta thalassemia major, so that those with gonadal fail-
ure may start as soon as possible the replacement therapy.
Patients with normal gonadal function should re-evaluate pe-
riodically their sexual hormone function because hypogo-
nadism may develop after puberty and involve both pituitary
and the gonads. In patients who do not respond adequately
to HRT, other possible causes of osteoporosis should be
screened and bisphosphonates could be added to the substi-
tution therapy.
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Figure 2 - Z score differences between eugonadal and hypogonadal thalassemic patients.
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